Navigation Links
Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
Date:4/4/2011

d unchanged in the urine within 24 hours post-dose.  At the highest dose (30 microgram/kg/min), 33 percent of patients met a pre-specified criterion for termination of treatment due to a fall in systolic blood pressure of greater than or equal to 20 millimeters of mercury. No severe adverse events were observed.

Doug Cowart, Pharm D., FABCP, RAC, Cardioxyl's Executive Vice President, Development and Regulatory Affairs, said, "These initial clinical results are consistent with our preclinical studies and support that CXL-1020 has  a predictable pharmacokinetic profile, an acceptable safety profile and appears to be well tolerated by patients."

About CXL-1020

Cardioxyl has developed a nitroxyl chemistry platform technology that serves as the foundation for the company's drug discovery efforts. In research published by Cardioxyl's scientific founders from Johns Hopkins University, nitroxyl was shown to have positive vasodilatory and direct myocardial effects.  CXL-1020, a proprietary nitroxyl donor, is Cardioxyl's lead compound for the intravenous treatment of acute decompensated heart failure (ADHF).  A prodrug, CXL-1020 once administered, chemically converts into an active nitroxyl (HNO) compound and an organic byproduct.   In pre-clinical models of heart failure, CXL-1020 improves cardiovascular performance by enhancing the contractility (inotropy) and relaxation (lusitropy) of the failing heart and dilating the peripheral vasculature (vasodilation), without increasing heart rate or myocardial oxygen consumption.  Cardioxyl completed a Phase I/IIa safety and dose-escalation study of CXL-1020 in stable chronic heart failure subjects and has announced initiation of a Phase IIa trial. Based on all pre-clinical studies to date, CXL-1020 is anticipated to improve the symptoms, hemodynamics and clinical status of patients with ADHF.

About Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is
'/>"/>

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- According to a new market research ... Device, Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... reach $56.50 Billion by 2020, growing at a CAGR ... 235 market data Tables and 71 Figures spread through ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis ... that it has earned a $4 million milestone ... ) associated with the initiation of a Phase ... multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase ... to evaluate the efficacy and safety of plazomicin ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 Specialty ... in Westlake, OH, announces that they have achieved ... PowerServer, a Complete Certified Ambulatory EHR-certified system developed ... Specialty Teleradiology had a non MU compliant PACS ... their business grew from a niche in oncology ...
(Date:9/18/2014)... Doylestown, PA (PRWEB) September 18, 2014 ... month by successfully launching its first product a mere ... F PRIME™ is a high performance glycan release enzyme ... assurance, glycobiology research, and the basis for tissue pathology ... Bulldog Bio (Portsmouth, NH) for the North American market ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader in ... promotion for its maternity wedding outfits. Now, all the ... maternity wedding dresses on its website. , ... consumers. The company’s development manager believes the cheap maternity ... The current special offer will last until September 29, ...
(Date:9/17/2014)... 2014 Today, Fecbek, a leading dress manufacturer ... special occasion gowns. These are a lot of beautiful A-line ... new range. , A skirt is a tube- or ... or part of the legs. In the western world, skirts ... be a draped garment which is made out of a ...
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that ... occasion outfits, has released its 2014 empire waist ... has launched a big sale for these new and ... deeply discounted rates, from 15 to 65 percent off. ... on using comfortable to wear materials. Its elegant items ...
Breaking Medicine News(10 mins):Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com Has Recently Announced Its New Series of Delicate Special Occasion Gowns Online 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2
... Sweden: Two trials presented at the Heart Failure Congress 2011, ... European Society of Cardiology (HFA of the ESC), will help ... heart failure (CHF) in whom telemedical management delivers benefits. ... Late Breaking Session 1 - revealed that telemonitoring showed significant ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... benefits of robotic surgery on their websites without solid ... researchers report. In fact, four out of 10 ... robotic surgery is better than conventional surgery, an assertion ...
... May 21 (HealthDay News) -- As summer approaches and ... experts say. "We are not invincible when it ... an athletic trainer with the University of Tennessee at ... Medical and Science Advisory Board, in a news release ...
... chemotherapy is used to kill cancer cells, it can also ... bone marrow and blood cells, often limiting the ability to ... Cancer Research Center reported at today,s annual meeting of the ... one possible approach to reduce this toxic effect on bone ...
... York, NY (May 20, 2011)The American Federation for Aging Research ... 83 advanced fellows and junior faculty at 27 Centers of ... This effort, funded with support from the John A. Hartford ... create the cadre of academic leaders in geriatrics. As our ...
... , FRIDAY, May 20 (HealthDay News) -- Treating chronic ... and function, according to a new study. Prior research ... problems and reduced gray matter in brain areas that play ... pain, such as anxiety and depression. But it wasn,t clear ...
Cached Medicine News:Health News:Telemonitoring can improve overall survival of HF patients 2Health News:Telemonitoring can improve overall survival of HF patients 3Health News:Telemonitoring can improve overall survival of HF patients 4Health News:Telemonitoring can improve overall survival of HF patients 5Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 2Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 3Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 4Health News:Keeping Cool in the Heat 2Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:AFAR announces the 2011 Hartford Scholars in Geriatric Medicine 2
100cc silicone evacuator with hubless flat drain and trocar...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Medicine Products: